Načítá se...
Clinical Trial of Oral Nelfinavir Before and During Radiation Therapy for Advanced Rectal Cancer
PURPOSE: Nelfinavir, a PI3-kinase pathway inhibitor, is a radiosensitizer which increases tumor blood flow in preclinical models. We conducted an early-phase study to demonstrate the safety of nelfinavir combined with hypofractionated radiotherapy (RT) and to develop biomarkers of tumor perfusion an...
Uloženo v:
Vydáno v: | Clin Cancer Res |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
2016
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4835023/ https://ncbi.nlm.nih.gov/pubmed/26861457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1489 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|